Application of matrine-type alkaloids in the preparation of anti-inflammatory drugs
Activating the PI3K/AKT/mTOR signaling pathway through matrine-type alkaloids (flavesine G), the problem of anti-inflammatory deficiency in the treatment of neuroinflammatory-related diseases is solved, and significant anti-inflammatory and anti-neuroinflammatory effects are achieved, providing targeting nerves Effective treatment plans for inflammation and related diseases.
Patent Information
- Application Number
- CN202210893423.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-07-27
AI Technical Summary
The prior art has failed to effectively solve the treatment of neuroinflammatory-related diseases, especially in terms of anti-inflammatory and anti-neuroinflammatory diseases, which makes it difficult to effectively relieve the disease treatment.
Using matrine alkaloids (flavesine G, K49) as an anti-inflammatory drug, significantly reduces the expression of IL-6 and TNF-α in microglia and reduces ROS and NO Release, inhibit the expression of Iba-1, and is used to prepare anti-neuroinflammatory drugs, prevent or treat inflammation-related diseases.
flavesine G significantly reduces the expression of inflammatory factors, improves the damage to learning and memory ability, has significant anti-inflammatory activity, and is non-toxic, providing a potential treatment plan for neuroinflammatory and related diseases.
Smart Images

Figure CN115089581B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to the application of matrine-type alkaloids in the preparation of anti-inflammatory drugs. Background Art
[0002] Inflammation is a defensive reaction of the body to stimulation, manifested as redness, swelling, heat, pain and dysfunction. Inflammation can be infectious inflammation caused by infection or non-infectious inflammation not caused by infection. When the biological body develops a vascular system, once it is affected by various damaging factors in the internal and external environment, a complex and complete inflammatory process characterized by vascular reaction and the above characteristics will appear. Inflammation in the body is divided into local, short-term acute inflammation and systemic chronic inflammation. In short, inflammation is the basic pathological process of various inflammatory-related diseases.
[0003] Neuroinflammation refers to the response of the central nervous system (CNS) to injury or disease. It covers a wide range, including complex cascade reactions coordinated by nerve cells and non-neuronal cells, all of which are aimed at protecting the CNS. The neuroinflammatory response process is very complex and has many influencing factors. Any slight imbalance may have serious consequences and hinder the recovery of the CNS.
[0004] In the human brain, neuroinflammation, viral or bacterial infection, etc. can stimulate microglial activation and produce proinflammatory cytokines, such as TNF-α, IL-6, IL-1β, NO and prostaglandin E2 (PGE2). These inflammatory mediators not only have toxic effects on neurons, leading to neuronal degeneration or death, but also stimulate astrocytes to produce more neurotoxic factors, thereby aggravating neuroinflammation.
[0005] Under normal circumstances, the harmful part of reactive oxygen species (ROS) can be neutralized by the antioxidant system. When the ROS produced exceeds the clearance capacity of the antioxidant system, a large amount of protein oxidation and lipid peroxidation will occur, leading to oxidative damage, cell degeneration and even functional decline. The mechanism by which ROS causes brain tissue damage is not very clear, but existing studies have shown that ROS can trigger a variety of molecular cascade reactions, increase the permeability of the blood-brain barrier, change brain morphology, and thus cause neuroinflammation and neuronal death. The oxidative damage caused by ROS can further cause DNA damage, telomere shortening, cell apoptosis and aging. Oxidative damage can lead to an increase in ROS, which in turn leads to oxidative damage, which continuously exacerbates neuroinflammation. ROS can cause protein misfolding and abnormal aggregation, which is a classic sign of many neurodegenerative diseases (such as AD and PD).
[0006] Neuroinflammation plays a key role in the development and progression of a variety of brain diseases and is considered an important pathological mechanism in the occurrence of brain trauma, encephalitis, stroke, cerebral ischemia, and neurodegenerative diseases. Exposure to pathogens in peripheral tissues can trigger neuroimmune signaling and microglial responses that are different from those in CNS infections. Viral components (i.e., poly-IC) or bacterial components (i.e., lipopolysaccharide, LPS) are often used to simulate peripheral infections and study neuro-immune interactions. Immune cells in peripheral tissues influence the proinflammatory signaling cascade of other immune mediators. In particular, cytokines in the blood circulation promote the secretion of IL-1β by macrophages in periventricular organs, as well as by perivascular macrophages and endothelial cells of the neurovasculature. These proinflammatory signals are transmitted and propagated by microglia. These microglial responses mediate important pathophysiological processes that promote survival (e.g., fever) and behavioral responses (e.g., lethargy). This microglial activation mediated by peripheral inflammation is transient and generally does not cause obvious neuropathological changes. Recent studies have shown that peripheral administration of LPS can lead to transient BBB disruption and microhemorrhages in the brain. Neuroimmune interactions may contribute to the observed changes in inflammatory mediators in the brain, but further studies are needed to determine these mechanisms. Microglial function is altered after peripheral infection because viral components (i.e., poly-IC) or bacterial components (i.e., lipopolysaccharide, LPS) generally do not reach the brain parenchyma, and the effects of LPS are dependent on the route of administration, dose, and duration of exposure. Therefore, studies using LPS need to consider the extent to which neuro)immune signaling pathways are transmitted to microglia and the brain, as well as the role of peripheral inflammation in neuroinflammation in these models.
[0007] In the context of CNS infection, neuroinflammation induced by microglia activation is important for the detection and elimination of pathogens, but it is not without consequences. For example, bacterial infection of the subarachnoid space leads to the secretion of a large number of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), by astrocytes, endothelial cells, and microglia, which can cause inflammation of the meninges. These cytokines also activate endothelial integrins and stimulate chemokine secretion, promoting the recruitment of peripheral leukocytes. In addition, microorganisms such as Streptococcus pneumoniae, which are associated with bacterial meningitis, can penetrate the blood-brain barrier (BBB), and microglia directly react with bacterial cell walls in the parenchyma. In vitro models and rodent studies have shown that components of the pneumococcal cell wall cause microglia to produce nitric oxide and a variety of different cytokines and chemokines, thereby increasing leukocyte extravasation into the parenchyma. On the one hand, invading pathogens will trigger apoptosis through bacterial exotoxins, ultimately leading to cell death. On the other hand, neuroinflammation caused by cytokines and ROS in the immune system can prevent infection, but the inflammatory response comes at the cost of associated tissue damage.
[0008] When there is damage or infection, microglia are activated by endogenous stimulation and shrink into an amoeba shape. After cerebral ischemia, damaged neurons release neurotransmitters, damage-associated molecular patterns (DAMPs), high-mobility group protein B1 (HMGB1) protein and ROS, which in turn activate microglia. Microglia are highly plastic cells that can switch between different phenotypes. Studies in experimental models of autoimmune encephalomyelitis have shown that the inflammatory response after tissue injury has a dual role. When the middle cerebral artery of mice is briefly occluded, the infiltration of microglia and macrophages reaches a peak 48-72 hours after ischemic injury. In spontaneously hypertensive stroke-prone rats, brief middle cerebral artery occlusion (as short as 15 minutes) leads to the activation of microglia, after which these cells migrate to the ischemic lesions and remain close to neurons in a process called "capping", which helps to quickly remove damaged neurons.
[0009] AD is a highly prevalent chronic neurodegenerative disease, accounting for 60-70% of dementia worldwide. According to the mainstream amyloid (Aβ) and tau protein cascade hypothesis, the accumulation of Aβ deposits and neurofibrillary tangles containing hyperphosphorylated Tau in the brain triggers AD. Microglia remove Aβ aggregates by uptake, local degradation, or degradation by releasing neprilysin. Therefore, there is a delicate balance between the removal and synthesis pathways of Aβ protein. Neuronal damage or Aβ overproduction disrupts this balance, causing Aβ protein aggregation and plaque formation in the extracellular compartment of the brain. A variety of receptors, such as different toll-like receptors (mainly TLR4 and TLR6) and NACHT, LRR, CD36, and pyrin domain-containing protein (NLRP3), can bind to Aβ in microglia. They are also stimulated by DAMPs, and when Aβ binds to CD36, TLR4, or TLR6 receptors, microglia are activated and produce proinflammatory cytokines and chemokines. The cytokines released by activated microglia are mainly TNF-α and IL-1β. TNF-α binds to TNF receptors on the cell membrane and induces the extrinsic pathway of apoptosis. Aβ itself can induce the release of various proinflammatory cytokines, such as IL-1α, IL-1β, IL-6, and TNF-α. Aβ makes astrocytes and microglia more sensitive to stimulation and more likely to secrete IL-1β, which accelerates the production of an inflammatory response. Therefore, Aβ induces its own production several times through this mechanism, leading to an increase in cytokine-mediated neuroinflammation.
[0010] With the acceleration of the aging of Chinese society, the incidence and prevalence of inflammation and neuroinflammation-related diseases are increasing year by year. These diseases bring huge economic losses to society and impose heavy burdens on patients and their families. Current research progress shows that antagonizing neuroinflammation and reducing inflammation-induced nerve damage are the key to treating neuroinflammation-related diseases. Therefore, the study of new specific drugs with anti-inflammatory activity has important medical value and social significance.
[0011] The matrine-type alkaloid (flavesine G, hereinafter abbreviated as K49) of the structure provided by the present invention is a compound separated from the traditional Chinese medicine Sophora flavescens. The inventor of the present invention disclosed in previous relevant literature that it has an anti-hepatitis B virus effect. However, the prior art does not disclose that the matrine-type alkaloid of the structure has an anti-inflammatory effect, let alone an anti-neuroinflammatory effect. The chemical structure of the matrine-type alkaloid is as follows:
[0012] Summary of the invention
[0013] In order to overcome at least one of the technical problems existing in the prior art, the present invention first provides the use of matrine-type alkaloids in the preparation of anti-inflammatory drugs or anti-neuroinflammatory drugs.
[0014] The above technical problems to be solved by the present invention are achieved through the following technical solutions:
[0015] The present invention first provides the use of matrine-type alkaloids in the preparation of anti-inflammatory drugs, and the chemical structural formula of the matrine-type alkaloids is as follows:
[0016]
[0017] The present invention also provides the use of matrine-type alkaloids in the preparation of anti-neuroinflammatory drugs, and the chemical structural formula of the matrine-type alkaloids is as follows:
[0018]
[0019] The inventors of the present invention surprisingly found in their research that the matrine-type alkaloid (flavesine G (K49)) of the above structure of the present invention has very excellent anti-inflammatory and anti-neuroinflammatory effects; and its anti-inflammatory and anti-neuroinflammatory effects are significantly higher than those of other matrine-type alkaloids.
[0020] Further studies in the present invention show that flavesine G (K49) can significantly reduce the expression levels of IL-6 and TNF-α produced in LPS-induced microglia and reduce the release of ROS and NO; inhibit the expression of Iba-1 in microglia; and verify that flavesine G (K49) activates the PI3K / AKT / mTOR signaling pathway to produce anti-inflammatory effects.
[0021] The present invention also provides the use of matrine-type alkaloids in the preparation of drugs for preventing or treating diseases related to inflammation or neuroinflammation. The chemical structural formula of the matrine-type alkaloids is as follows:
[0022]
[0023] Preferably, the drugs for diseases related to inflammation or neuroinflammation include skin inflammation, arthritis, gout, hepatitis, brain trauma, encephalitis, stroke, cerebral ischemia and neurodegenerative diseases.
[0024] The inventors further studied and showed that flavesine G (K49) can also significantly reduce the expression of inflammatory factors in the mouse hippocampus, inhibit the expression of glial cell Iba-1 and astrocyte GFAP protein, and increase the expression of PSD95 and BCL2 proteins; thus, it can be seen that the use of flavesine G (K49) in the preparation of drugs for the treatment or prevention of neuroinflammatory or neurodegenerative diseases has important application prospects.
[0025] Preferably, the neurodegenerative diseases include Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
[0026] The inventors further studied and showed that the Flavesine G (K49) can also reduce the expression of inflammatory factors in the mouse hippocampus and intervene in LPS-induced learning and memory disorders in mice; thus, it can be seen that the use of flavesine G (K49) in the preparation of drugs for the treatment or prevention of Alzheimer's disease has important application prospects.
[0027] The present invention also provides the use of matrine-type alkaloids in the preparation of a drug for preventing or treating memory disorders. The chemical structural formula of the matrine-type alkaloids is as follows:
[0028]
[0029] The inventors further studied and found that after administration of flavesine G (K49), the learning and memory impairment caused by LPS in mice was significantly improved. Therefore, flavesine G (K49) has important application prospects for the preparation of drugs for treating or preventing memory disorders.
[0030] Preferably, the drug is further prepared into tablets, granules, capsules, oral solutions or injections.
[0031] Beneficial effects:
[0032] (1) The present invention provides for the first time the use of the matrine-type alkaloid (flavesine G (K49)) of the above-mentioned structure of the present invention in the preparation of anti-inflammatory drugs, anti-neuroinflammatory drugs, and in the preparation of drugs for preventing or treating diseases related to inflammation or neuroinflammation and in the preparation of drugs for preventing or treating memory disorders.
[0033] (2) In in vitro cell experiments, flavesine G (K49) has a significant anti-inflammatory activity, and its anti-inflammatory mechanism is that flavesine G (K49) activates the PI3K / AKT / mTOR signaling pathway. In in vivo animal experiments, flavesine G (K49) can also significantly reduce the expression of inflammatory factors in the hippocampus of inflammatory model mice, inhibit the expression of glial cells Iba-1 and astrocyte GFAP, increase the expression of PSD95 and BCL2 proteins, and significantly improve the learning and memory impairment of mice caused by inflammation. Existing results show that the use of flavesine G in the preparation of drugs for the treatment of neuroinflammation and related diseases has important application prospects.
[0034] (3) The present invention discovered the optimal dose and time point of flavesine G (K49). We set the effect of different doses of flavesine G (K49) on the expression level of microglia inflammatory factors at different time points and obtained the optimal dose and time point. This provides a potential therapeutic drug for neuroinflammation and inflammation-related diseases.
[0035] (4) The present invention found that flavesine G (K49) has no toxicity to microglia. We tested the effects of different doses of flavesine G (K49) on microglia viability at different time points to confirm whether the compound is toxic. It was verified that flavesine G (K49) has no toxicity. This provides safety and availability for the further use of the compound in the prevention and treatment of neuroinflammation and neurodegeneration-related diseases.
[0036] (5) The present invention found that flavesine G (K49) has good efficacy both in vivo and in vitro. Flavesi (K49) can also significantly improve the learning and memory impairment of mice, and is a potential drug for early intervention of AD. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The effects of different doses of flavesine G (K49) on the release of proinflammatory factors in the supernatant of microglia induced by LPS and the effects of flavesine G (K49) on the release of proinflammatory factors in the supernatant of microglia induced by LPS under different pre-protection time conditions. Figure 1 A is the expression level of IL-6 at different doses. Figure 1 B is the expression levels of IL-6 and TNF-α at different time points.
[0038] Figure 2This is a graph showing the effects of different doses of flavesine G (K49) on microglial activity at different time points detected by CCK8 method.
[0039] Figure 3 The results of flavesine G (K49) on the ROS and NO levels produced by LPS-induced microglia. Figure 3 A is the NO expression level diagram, Figure 3 B is the ROS Western Blot image.
[0040] Figure 4 This is the effect of flavesine G (K49) on the expression level of Iba-1, and the result of immunofluorescence detection.
[0041] Figure 5 This study explores the mechanism of flavesine G (K49) on LPS-induced microglia, which may activate the PI3K / AKT / mTOR signaling pathway.
[0042] Figure 6 This is the result of flavesine G (K49) improving the learning and memory impairment of mice. The spontaneous alternation of each group was statistically analyzed by Y maze test.
[0043] Figure 7 This is the result of the expression of inflammatory factors in the hippocampus of mice after the action of flavesine G (K49). Figure 7 A is the expression level of IL-1β, Figure 7 B is the IL-6 expression level, Figure 7 C is the expression level of TNF-α.
[0044] Figure 8 This is the overall result of Western Blot in mouse hippocampus tissue.
[0045] Fig. 9 These are the immunofluorescence results of Iba-1 and GFAP in mouse hippocampal tissue. Figure A is the immunofluorescence image of Iba-1, and Figure B is the immunofluorescence image of GFAP. DETAILED DESCRIPTION
[0046] The present invention is further explained below in conjunction with specific examples, but the examples do not limit the present invention in any form.
[0047] Example 1 The ELISA method was used to detect the content of inflammatory factors in the cell supernatant under different dosage concentrations and different pre-protection time conditions.
[0048] (1) Take microglia in the logarithmic growth phase, discard the old culture medium, wash once with 4°C precooled PBS, add 2 ml of fresh culture medium, blow all the cells off, centrifuge at 1000 rpm for 5 min, count the cells and centrifuge at 3×10 4 Cells were inoculated per well in a 24-well plate, 500 μl of culture medium was added to each well, and the plate was placed in an incubator for 24 hours. Groups were set up: normal control group, LPS (1 μg / ml) model group, and flavesine G (K49) + LPS (1 μg / ml) group. Flavesine G (K49) was used at four concentrations of 12.5 μM, 25 μM, 50 μM, and 100 μM to pre-protect cells for 12 hours. After that, LPS was added to the LPS model group and the drug-treated group for another 12 hours. The cell culture fluid of each group was collected and centrifuged at 3000 rpm for 15 minutes. The supernatant was taken to detect the concentrations of IL-6 and TNF-α. The results are shown in Figure 1 As shown in Figure A, when the drug concentration is 25 μM, flavesine G (K49) has the best effect in inhibiting IL-6 expression. Therefore, we concluded that within a certain dose range, the anti-inflammatory effect of flavesine G (K49) is dose-dependent.
[0049] (2) With other experimental conditions unchanged, the drug was administered to protect microglia for 3h, 6h, 12h, and 24h, and then the supernatant of each group was collected to detect inflammatory factors. Figure 1 As shown in Figure B, there was no significant difference in the expression levels of IL-6 and TNF-α in each group at different pre-protection times, that is, the anti-inflammatory effect of flavesine G (K49) was not weakened by the extension of the pre-protection time. It also shows that flavesine G (K49) can produce anti-inflammatory effects in a short time.
[0050] Example 2 The CCK8 method was used to detect the effects of different doses of flavesine G (K49) on microglial activity at different time points.
[0051] Take the microglia in the logarithmic growth phase, discard the old culture medium, add an appropriate amount of PBS to wash, and then add an appropriate amount of fresh culture medium to blow until most of the cells are blown down; this experiment has set up: blank group, normal control group, 50μM, 100μM, 200μM, 400μM, 800μM flavesine G (K49) at 12h, 24h, 48h cell activity. 4The cells were inoculated into a 96-well plate at a density of 100 μl of culture medium per well. According to the edge effect, the edge wells of the plate were filled with an equal amount of PBS. After the cells adhered to the wall, the old culture medium was aspirated and replaced with drug-containing culture medium. The cells were cultured for 12 h, 24 h, and 48 h, respectively. 10 μl of CCK8 solution was added to each well and cultured for 2 h at 37 ° C and 5% CO2. The microplate reader was preheated in advance, and the OD value at a wavelength of 450 nm was measured and recorded and processed. The results are shown in Figure 2. Figure 2 As shown, flavesine G(K49) had no effect on the activity of microglia.
[0052] Example 3 Effect of Flavesine G (K49) on the expression levels of NO and iNOS.
[0053] (1) NO detection
[0054] a. The cell culture method is the same as in Example 1, and the cell supernatant is the desired test sample.
[0055] b. Take out Griess Reagent I and II from the kit in advance and place them at room temperature. Dilute the standard with cell culture medium (DMEM + 10% FBS) to concentrations of 0, 1, 2, 5, 10, 20, 40, 60, 100 μM.
[0056] c. Prepare a 96-well plate, add 50 μl of standard and sample to each well, and set up 3 replicate wells for each group of samples;
[0057] d. Add Griess Reagent I that has returned to room temperature to each well, 50 μl per well;
[0058] e. Add Griess Reagent II that has returned to room temperature to each well, 50 μl per well;
[0059] f. Preheat the microplate reader in advance and detect the absorbance of the sample at 540nm;
[0060] g. Draw a standard curve and calculate the concentration of NO in the sample.
[0061] The results are as follows Figure 3 As shown in Figure B, flavesine G (K49) can reduce the expression level of NO produced by microglia induced by LPS.
[0062] (2) The expression level of iNOS protein was detected by Western Blot.
[0063] a. The protein concentration of the samples was determined by the BCA method, and the sample loading volume (20 μg / 10 μl) was consistent;
[0064] b. Prepare separation gel and concentration gel;
[0065] c. Electrophoresis: Add 10 μl of sample to each well and perform electrophoresis at 80V for 30 minutes. When the sample enters the separation gel, adjust the voltage to 120V for 60 minutes until bromophenol blue enters the bottom of the separation gel.
[0066] d. Transfer: Use wet transfer method, first activate the PVDF membrane with methanol for 3 minutes in advance, and then place the sponge, filter paper, gel, PVDF, filter paper, sponge in the order from negative electrode to positive electrode, and transfer at a constant current of 300mA for 90 minutes in pre-cooled transfer buffer; the whole process is carried out in ice water.
[0067] e. After the transfer, the membrane was placed in a culture dish containing 5% (w / v) skim milk powder prepared with TBST, blocked at room temperature for 90 min, and then washed three times with TBST, each time for 5 min;
[0068] f. Primary antibody incubation: dilute the primary antibody with primary antibody diluent, incubate at 4°C overnight, then wash 3 times with appropriate amount of TBST buffer on a shaker, 10 min each time;
[0069] g. Secondary antibody incubation: dilute the secondary antibody with TBST, incubate at room temperature for 1 hour, then wash 3 times with appropriate amount of TBST buffer on a shaker, 10 minutes each time;
[0070] h. Chemiluminescence and first use: Drop fresh BeyoECLplus working solution on the membrane, make sure the working solution covers the membrane, and use ALLIANCE4.7 instrument to collect fluorescence signals.
[0071] The results are as follows Figure 3 Figure B shows the result of ROS protein expression level. Flavesine G (K49) can reduce the ROS protein content produced by LPS-induced microglia.
[0072] Example 4 Effect of Flavesine G (K49) on the expression level of Iba-1.
[0073] Immunofluorescence staining
[0074] Day 1:
[0075] a. Prepare sterile slides in a 24-well plate in advance and place under UV light for 1 hour;
[0076] b. Cell culture and grouping methods are the same as in Example 1;
[0077] c. Add sterile PBS to the 24-well plate and wash for 3×3 minutes, fix the slides with 4% paraformaldehyde for 30 minutes, and then soak the slides with PBS for 3×3 minutes;
[0078] d. Permeabilize with 0.5% Triton X-100 (prepared in PBS) at room temperature for 15 min, then wash the slides with PBS for 3×3 min;
[0079] e. Add 200 μl of 5% BSA blocking solution to each well and block at room temperature for 1 hour;
[0080] f. Aspirate the blocking solution, do not wash, add 150 μl of diluted primary antibody to each well, and block at 4°C overnight.
[0081] the next day:
[0082] g. Recover the primary antibody, wash with PBST for 3 min × 3 times, add 150 μl fluorescent secondary antibody (containing DAPI) to each well, and incubate for 2 hours in the dark;
[0083] h. Recover the secondary antibody, wash with PBST for 3 min × 3 times, absorb the liquid on the slide with filter paper, seal the slide with a sealing medium containing a fluorescence quencher, and store it in a dry and dark place. Observe and collect images under a fluorescence microscope one day later.
[0084] The results are as follows Figure 4 As shown, the Iba-1 positive staining of cells treated with flavesine G (K49) was less than that of the LPS group, indicating that flavesine G (K49) could inhibit the activation of microglia to some extent.
[0085] Example 5 Study on the mechanism of action of Flavesine G (K49) on microglia.
[0086] The Western Blot method was used to detect the expression level of each protein, and the method was the same as in Example 3. Figure 5 As shown, flavesine G(K49) activated the PI3K / AKT / mTOR signaling pathway.
[0087] Example 6 Y-maze experiment to detect the short-term spatial learning and memory ability of mice;
[0088] The Y-maze test consists of a Y-shaped white maze and the Ethovision XT behavioral analysis system. The three arms of the Y-maze are 50 cm long, and the angle between two adjacent arms is 120°. There is a camera directly above the Y-maze connected to the Ethovision XT behavioral analysis software to record the mouse activity trajectory and analyze the data. The environment should be kept quiet during the test, and the room temperature should be maintained at 23±1℃.
[0089] a. Place the mouse into the Y-maze from the center and use Ethovision XT software to record its activity trajectory in the Y-maze for 10 min;
[0090] b. After the last mouse finishes the test, clean the Y maze with 75% alcohol and put the next mouse in after the alcohol smell has dissipated;
[0091] c. After all mice finished the test, the spontaneous alternation behavior of the mice was analyzed using Ethovision XT software, and then the percentage was calculated = actual alternation / maximum alternation×100%, and the percentage was the score of each mouse.
[0092] The results are as follows Figure 6 As shown, flavesine G(K49) can improve the short-term spatial learning and memory ability of mice.
[0093] Example 7 Expression of inflammatory factors in the hippocampus of mice after the action of flavesine G (K49).
[0094] Sample preparation: Take out the frozen tissue at -80℃ and weigh it. Add pre-cooled 0.01M PBS containing protease inhibitors at a mass: volume ratio of 1:5 (mg:mL). Prepare the homogenate supernatant in the same way as extracting tissue protein, and determine the total protein content. Use ELISA kits to detect the concentrations of IL-1β, IL-6 and TNF-α respectively. The results are as follows Figure 7 Shown: flavesine G (K49) can inhibit the expression of inflammatory factors.
[0095] Example 8 The protein expression in the hippocampal tissue of each group of mice was observed by Western Blot technology.
[0096] The expression levels of each protein were detected by Western Blot, using the same method as in Example 3.
[0097] Among them are PSD95 protein and BCL2 protein. PSD95 is a postsynaptic protein, as shown in the figure: the protein expression level decreases after LPS stimulation, indicating that LPS can damage postsynaptic proteins. After adding flavesine G (K49), PSD95 protein increases, indicating that the drug can reduce protein damage. BCL2 is an anti-apoptotic protein, such as Figure 8 As shown, LPS can reduce the protein, indicating an increase in apoptosis. Adding flavesine G (K49) can reduce apoptosis.
[0098] Example 9 used immunofluorescence technology to observe the expression levels of Iba-1 and GFAP in the mouse brain.
[0099] Immunofluorescence staining
[0100] a. Take out the frozen sections stored at -80℃ and dry them in a dark room at room temperature for 30 minutes.
[0101] b. Wash three times in 0.01M PBS, 5 min each time, with gentle shaking.
[0102] c. Wipe off the moisture, circle the location of the tissue with an immunohistochemistry pen, add a drop of PBS to cover the specimen, and absorb the PBS after the surrounding moisture is completely dry.
[0103] d. Block with the prepared blocking solution at room temperature for 1 hour, then add the diluted primary antibody to cover the specimen, place it in a humidified box, and incubate at 4°C for the corresponding time (36 to 48 hours for synaptic quantitative staining, and 16 to 24 hours for the rest).
[0104] e. Remove the primary antibody and immerse the sections in 0.01 M PBS and wash three times, 15 min each time.
[0105] Protect from light, carefully absorb excess water around the specimen with absorbent paper, add diluted secondary antibody, and incubate at room temperature for 2 hours in a light-proof humid box.
[0106] f. Immerse in 0.01 M PBS to wash away unbound secondary antibody. Wash three times, 15 minutes each time.
[0107] g. After absorbing the water around the specimen, add diluted DAPI and stain for 10 minutes in the dark. Then continue washing 2 more times, 5 minutes each time.
[0108] h. After adding anti-fading sealing agent to the specimen, cover it with a cover glass. This process is carried out in the dark, and then the sections that have been sealed are kept in the dark at 4℃, and examined under a microscope and photographed as soon as possible.
[0109] Iba-1 is a marker of microglia. Fig. 9 As shown in the figure, LPS can activate microglia and release inflammatory factors. Adding flavesine G can inhibit activation and reduce the release of inflammatory factors; GFAP is a marker of astrocytes. As shown in the figure, LPS can activate astrocytes and release inflammatory factors. Adding flavesine G can inhibit activation and reduce the release of inflammatory factors.
[0110] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Application of matrine-type alkaloids in the preparation of drugs for anti-neuroinflammatory effects, It is characterized in that The The chemical structure of matrine-type alkaloids is as follows: 。 2. Use of matrine-type alkaloids in the preparation of drugs for preventing or treating memory impairment caused by neuroinflammation, It is characterized in that The chemical structural formula of the matrine-type alkaloids is as follows: 。
